At a glance
- Originator Merck Sante
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 03 Sep 1998 No-Development-Reported for Atherosclerosis in France (Unknown route)
- 03 Sep 1998 No-Development-Reported for Hyperlipidaemia in France (Unknown route)
- 24 Jul 1995 Preclinical development for Atherosclerosis in France (Unknown route)